NCT03701698 is a Phase 2 clinical trial of Ruxolitinib Oral Tablet in Acute GVHD, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT03701698?

Interventions in NCT03701698: Ruxolitinib Oral Tablet, Methylprednisolone.

What condition does NCT03701698 study?

NCT03701698 studies Acute GVHD.

Is NCT03701698 still recruiting?

NCT03701698 is currently terminated. Last updated 1 October 2024.

Last reviewed 2024-10-01 · How we verify

NCT03701698

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Terminated Phase 2 Last updated 1 October 2024

What this trial tests

Phase 2 trial testing Ruxolitinib Oral Tablet in Acute GVHD in 1 participant. Terminated before completion.

Timeline

1 November 2018

Primary endpoint
20 September 2024

20 September 2024

Quick facts

Lead sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	1
Start date	1 November 2018
Primary completion	20 September 2024
Estimated completion	20 September 2024
Sites	1 location across China

Drugs / interventions tested

Ruxolitinib Oral Tablet
Methylprednisolone (methylprednisolone) — full drug profile →

Conditions studied

Acute GVHD — all drugs for Acute GVHD →

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 70, any sex, with Acute GVHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease.
Jansen SA, Nieuwenhuis EES, Hanash AM, Lindemans CA. · · 2022 · cited 24× · PMID 35654837 · DOI 10.1038/s41385-022-00527-6

Verify or expand the search:

Other trials of Ruxolitinib Oral Tablet

Trials testing the same drug.

NCT04334044 — Treatment of SARS Caused by COVID-19 With Ruxolitinib · Phase 1, PHASE2 · completed
NCT04361903 — Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection · unknown

Other recruiting trials for Acute GVHD

Currently open trials in the same condition.

NCT04373057 — Prebiotic Galacto-oligosaccharide and Acute GVHD · Phase 1, PHASE2 · recruiting
NCT02611180 — Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease · active not recruiting

Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT06667466 — New Laser and Suction Sheath for Kidney Stone Treatment · not yet recruiting
NCT07043374 — Impact of Humid-Heat on Gut-Tryptophan-Stone Pathway · not yet recruiting
NCT07415226 — Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT07439120 — Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03701698 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 1 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03701698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing